Liquidia (LQDA) Shares Rise After Strong Q1 Earnings and Revenue Beat

Liquidia Corporation (NASDAQ:LQDA) shares gained astir 3% successful premarket trading connected Monday aft the biopharmaceutical institution reported first-quarter results that exceeded expert expectations connected some net and revenue.

The institution posted adjusted net per stock of $0.52, beating the statement estimation of $0.37 by $0.15.

Revenue Boosted by Strong YUTREPIA Sales

Quarterly gross totaled $132.86 million, comfortably supra expert expectations of $116.62 million.

Liquidia said nett merchandise income from YUTREPIA — its inhaled treprostinil pulverization therapy for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung illness — reached astir $129.9 cardinal during the quarter.

The institution noted that since YUTREPIA’s motorboat successful June 2025, the attraction has generated much than 4,500 unsocial diligent prescriptions and has been utilized to dainty astir 3,750 patients done April 30, 2026.

Profitability Continues to Improve

Liquidia reported its 3rd consecutive profitable quarter, posting nett income of $52.9 cardinal and adjusted EBITDA of $71.2 million.

“In its 3rd afloat 4th connected the market, YUTREPIA continued to show sustained uptake successful pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, accordant with its increasing adoption arsenic the preferred inhaled prostacyclin of choice,” said Chief Executive Officer Dr. Roger Jeffs.

Total gross of $132.9 cardinal besides included astir $3.0 cardinal successful work gross tied to a profit-sharing statement with Sandoz related to Treprostinil Injection sales.

The institution had reported nary merchandise income during the archetypal 4th of 2025.

Operating Expenses Rise Alongside Commercial Expansion

Research and improvement expenses accrued to $12.6 cardinal from $7.0 cardinal a twelvemonth earlier, chiefly driven by further objective spending tied to the L606 improvement program.

Selling, wide and administrative expenses roseate to $46.9 cardinal from $30.1 cardinal successful the prior-year period, reflecting accrued unit costs and commercialization spending associated with the YUTREPIA launch.

Cash Position Strengthens

Liquidia ended the 4th with currency and currency equivalents of $222.8 cardinal arsenic of March 31, 2026, up from $190.7 cardinal astatine the extremity of 2025.

Liquidity Services banal price